Indication
Esophageal
7 clinical trials
12 products
3 drugs
Product
REP 2139-MgClinical trial
Compassionate Use Access to REP 2139-Mg for the Treatment of Chronic HBV Infection or Chronic HBV / HDV Co-infectionStatus:
Product
Pegylated interferon alpha2aProduct
Astragalus PolysaccharidesClinical trial
PG2 Concurrent With Chemoradiation for Locally Advanced Esophageal CancerStatus: Active (not recruiting), Estimated PCD: 2023-02-03
Clinical trial
Effect of Botulinum Toxin Injection Into Upper Esophageal Sphincter on Swallowing Function in Patients With Medullary InfarctionStatus: Recruiting, Estimated PCD: 2024-12-12
Product
Botulinum toxin type AClinical trial
Phase I/II Evaluation of Oral Decitabine/Tetrahydrouridine as Epigenetic Priming for Pembrolizumab Immune Checkpoint Blockade in Inoperable Locally Advanced or Metastatic Non-Small Cell Lung Cancers, Esophageal Carcinomas, or Pleural MesotheliomasStatus: Terminated, Estimated PCD: 2021-10-06
Product
DecitabineProduct
TetrahydrouridineDrug
mFOLFOX6Clinical trial
Beta-blockers Or Placebo for Primary Prophylaxis of Oesophageal Varices (BOPPP Trial). A Blinded, UK Multi-centre, Clinical Effectiveness and Cost-effectiveness Randomised Controlled Trial.Status: Recruiting, Estimated PCD: 2026-12-01
Product
CarvedilolDrug
VarlilumabClinical trial
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal CancerStatus: Recruiting, Estimated PCD: 2034-12-30
Drug
T-VECProduct
EntinostatProduct
Montanide ISA-51 VG AdjuvantProduct
H1299 Cell LysatesClinical trial
The Effect of Oral Buspirone Hydrochloride on Esophageal Motility, Bolus Transit and Symptoms of Dysphagia, in Patients With Poor Esophageal Motility: A Randomized, Double-blind, Placebo Controlled, Cross-over Trial With HRiMStatus: Recruiting, Estimated PCD: 2024-09-30
Product
Buspirone Hydrochloride